| Revision as of 20:26, 28 October 2013 edit12.155.173.1 (talk)No edit summary← Previous edit | Revision as of 08:20, 8 November 2013 edit undoYobot (talk | contribs)Bots4,733,870 editsm Reference before punctuation detected and fixed using AWB (9585)Next edit → | ||
| Line 1: | Line 1: | ||
| {{Drugbox | {{Drugbox | ||
| | Watchedfields = changed | | Watchedfields = changed | ||
| Line 32: | Line 31: | ||
| | PubChem = 56842108 | | PubChem = 56842108 | ||
| | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | ||
| | DrugBank = |
| DrugBank = | ||
| <!--Chemical data--> | <!--Chemical data--> | ||
| }} | }} | ||
| The combination of the ] '''phentermine and topiramate''' (trade name '''Qsymia''', formerly '''Qnexa''') is a medication indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: ≥30 |
The combination of the ] '''phentermine and topiramate''' (trade name '''Qsymia''', formerly '''Qnexa''') is a medication indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: ≥30 kg/m<sup>2</sup> or ≥27 kg/m<sup>2</sup> (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia.<ref></ref> In clinical trials, Qsymia was associated with significant weight loss when compared with placebo.<ref></ref> This weight loss was associated with improvements in weight-related comorbidities such as improved glycemia, decreased blood pressure, and improved cholesterol.<ref></ref> | ||
| ⚫ | Qsymia was developed by ], Inc., a California pharmaceutical company.<ref></ref> ] is a sympathomimetic amine which acts as an ] and ].<ref></ref> ] is an ] that has weight loss side effects.<ref></ref> The exact mechanism of action for both drugs is unknown.<ref></ref> | ||
| ⚫ | On February 22, 2012, U.S. ] (FDA) advisors voted 20 to 2 to recommend that the FDA adopt phentermine/topiramate ER for chronic weight management.<ref></ref> On July 17, 2012, the U.S. FDA approved Qsymia as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: ≥30 kg/m<sup>2</sup> or ≥27 kg/m<sup>2</sup> (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia.<ref></ref> Qsymia is available in certified retail pharmacies nationwide and also available through a certified mail-order pharmacy network.<ref></ref> | ||
| ⚫ | Qsymia was developed by ], Inc., a California pharmaceutical company.<ref></ref> ] is a sympathomimetic amine which acts as an ] and ]. |
||
| ⚫ | On February 22, 2012, U.S. ] (FDA) advisors voted 20 to 2 to recommend that the FDA adopt phentermine/topiramate ER for chronic weight management.<ref></ref> On July 17, 2012, the U.S. FDA approved Qsymia as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: ≥30 |
||
| ==Available Doses== | ==Available Doses== | ||
| The following doses of phentermine IR (immediate-release) and topiramate ER were used in Phase 3 testing<ref></ref> |
The following doses of phentermine IR (immediate-release) and topiramate ER were used in Phase 3 testing:<ref></ref> | ||
| • Top dose: phentermine 15 |
• Top dose: phentermine 15 mg and topiramate ER 92 mg | ||
| • Recommended dose: phentermine 7.5 |
• Recommended dose: phentermine 7.5 mg and topiramate ER 46 mg | ||
| ⚫ | • Starting dose: phentermine 3.75 |
||
| ⚫ | • Starting dose: phentermine 3.75 mg and topiramate ER 23 mg | ||
| ==Safety and effectiveness== | ==Safety and effectiveness== | ||
| Qsymia clinical trials have shown significant weight loss among subjects receiving Qsymia when compared with placebo.<ref></ref> The Phase 3 56-week EQUIP and CONQUER studies showed an average weight loss of 8% to 11% with the recommended dose or top dose (ITT-LOCF).<ref></ref> In addition, 62% to 70% of subjects receiving the recommended dose or top dose of Qsymia achieved ≥5% weight by week 56 (ITT-LOCF).<ref></ref> | Qsymia clinical trials have shown significant weight loss among subjects receiving Qsymia when compared with placebo.<ref></ref> The Phase 3 56-week EQUIP and CONQUER studies showed an average weight loss of 8% to 11% with the recommended dose or top dose (ITT-LOCF).<ref></ref> In addition, 62% to 70% of subjects receiving the recommended dose or top dose of Qsymia achieved ≥5% weight by week 56 (ITT-LOCF).<ref></ref> | ||
| The most common adverse events which occurred at a rate ≥5% and ≥1.5 times placebo included paraesthesia (tingling in fingers/toes), dizziness, dysguesia, insomnia, ], and ].<ref></ref> | The most common adverse events which occurred at a rate ≥5% and ≥1.5 times placebo included paraesthesia (tingling in fingers/toes), dizziness, dysguesia, insomnia, ], and ].<ref></ref> | ||
| ⚫ | Qsymia is contraindicated in pregnancy, glaucoma, hyperthyroidism, during or within 14 days of taking monoamine oxidase inhibitors, and in patients with hypersensitivity or idiosyncrasy to sympathomimetic amines. Qsymia can cause an increase in resting heart rate.<ref></ref> | ||
| ⚫ | Qsymia is contraindicated in pregnancy, glaucoma, hyperthyroidism, during or within 14 days of taking monoamine oxidase inhibitors, and in patients with hypersensitivity or idiosyncrasy to sympathomimetic amines. Qsymia can cause an increase in resting heart rate.<ref></ref> |
||
| Qsymia can cause fetal harm. Data from pregnancy registries and epidemiology studies indicate that a fetus exposed to topiramate, a component of Qsymia, in the first trimester of pregnancy has an increased risk of oral clefts (cleft lip with or without cleft palate).<ref></ref> If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be apprised of the potential hazard to a fetus. Females of reproductive potential should have a negative pregnancy test before starting Qsymia and monthly thereafter during Qsymia therapy. Females of reproductive potential should use effective contraception during Qsymia therapy.<ref></ref> | Qsymia can cause fetal harm. Data from pregnancy registries and epidemiology studies indicate that a fetus exposed to topiramate, a component of Qsymia, in the first trimester of pregnancy has an increased risk of oral clefts (cleft lip with or without cleft palate).<ref></ref> If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be apprised of the potential hazard to a fetus. Females of reproductive potential should have a negative pregnancy test before starting Qsymia and monthly thereafter during Qsymia therapy. Females of reproductive potential should use effective contraception during Qsymia therapy.<ref></ref> | ||
| ==Qsymia Risk Evaluation and Mitigation Strategy (REMS)== | ==Qsymia Risk Evaluation and Mitigation Strategy (REMS)== | ||
| Qsymia was approved with a REMS to assure that benefits of treatment outweigh the risks.<ref></ref> Because of the teratogenic risk associated with Qsymia therapy, Qsymia is available through a limited program under the REMS. Under the Qsymia REMS, only certified pharmacies may distribute Qsymia. Further information, is available at www.QsymiaREMS.com or by telephone at 1-888-998-4887. |
Qsymia was approved with a REMS to assure that benefits of treatment outweigh the risks.<ref></ref> Because of the teratogenic risk associated with Qsymia therapy, Qsymia is available through a limited program under the REMS. Under the Qsymia REMS, only certified pharmacies may distribute Qsymia. Further information, is available at www.QsymiaREMS.com or by telephone at 1-888-998-4887.<ref></ref> | ||
| ==Key Publications== | ==Key Publications== | ||
| '''EQUIP''' | '''EQUIP''' | ||
| Investigated the safety and efficacy of the combination for 56 weeks in severely obese patients (BMI ≥35 |
Investigated the safety and efficacy of the combination for 56 weeks in severely obese patients (BMI ≥35 kg/m2); published in Obesity.<ref></ref> | ||
| '''CONQUER''' | '''CONQUER''' | ||
| A 56-week safety and efficacy trial, evaluating obese or overweight patients (BMI ≥27 and ≤45 |
A 56-week safety and efficacy trial, evaluating obese or overweight patients (BMI ≥27 and ≤45 kg/m2) with ≥2 weight-related comorbidities (such as type 2 diabetes, hypertension, dyslipidemia); published in ].<ref></ref> | ||
| '''SEQUEL''' | '''SEQUEL''' | ||
| A 52-week extension of CONQUER, collecting long-term data over 108 weeks.<ref></ref> | A 52-week extension of CONQUER, collecting long-term data over 108 weeks.<ref></ref> | ||
| ==Approval history== | ==Approval history== | ||
| In December 2009 VIVUS submitted a ] (NDA) to the FDA and on March 1, 2010, Vivus announced that the FDA accepted the NDA for review.<ref></ref> | In December 2009 VIVUS submitted a ] (NDA) to the FDA and on March 1, 2010, Vivus announced that the FDA accepted the NDA for review.<ref></ref> | ||
| In October 2010, the FDA announced its decision to not approve Qsymia in its current form and issued a Complete Response Letter (CRL) to VIVUS due to lack of long-term data and concerns about side effects including elevated heart rate, major adverse cardiovascular events, and birth defects.<ref></ref> | In October 2010, the FDA announced its decision to not approve Qsymia in its current form and issued a Complete Response Letter (CRL) to VIVUS due to lack of long-term data and concerns about side effects including elevated heart rate, major adverse cardiovascular events, and birth defects.<ref></ref> | ||
| ⚫ | The FDA expressed concerns about the potential for Qsymia to cause birth defects and requested that Vivus assess the feasibility of analyzing existing healthcare databases to determine the historical incidence of oral cleft in offspring of women treated with topiramate for migraine prophylaxis (100 mg).<ref></ref> | ||
| ⚫ | The FDA expressed concerns about the potential for Qsymia to cause birth defects and requested that Vivus assess the feasibility of analyzing existing healthcare databases to determine the historical incidence of oral cleft in offspring of women treated with topiramate for migraine prophylaxis (100 |
||
| In October 2011, VIVUS resubmitted the NDA to the FDA with responses to the issues addressed in the CRL. The FDA accepted the NDA in November 2011.<ref></ref> | In October 2011, VIVUS resubmitted the NDA to the FDA with responses to the issues addressed in the CRL. The FDA accepted the NDA in November 2011.<ref></ref> | ||
| On February 22, 2012, US FDA advisors on the Endocrine and Metabolism Advisory Committee voted 20 to 2 to recommend that the FDA adopt phentermine/topiramate ER for chronic weight management.<ref></ref> | On February 22, 2012, US FDA advisors on the Endocrine and Metabolism Advisory Committee voted 20 to 2 to recommend that the FDA adopt phentermine/topiramate ER for chronic weight management.<ref></ref> | ||
| The drug’s name was changed from Qnexa to Qsymia, and approved by the FDA on July 17, 2012.<ref></ref> | The drug’s name was changed from Qnexa to Qsymia, and approved by the FDA on July 17, 2012.<ref></ref> | ||
| On September 18, 2012, Qsymia became available on the US market.<ref></ref> | On September 18, 2012, Qsymia became available on the US market.<ref></ref> | ||
| ==Patents and other indications== | ==Patents and other indications== | ||
| Vivus currently has four U.S. patents covering Qsymia. |
Vivus currently has four U.S. patents covering Qsymia.<ref></ref> These patents are related to the product and methods of using the drug in various therapeutic applications. | ||
| Qsymia is also in phase 2 clinical development for the treatment of type 2 diabetes and ] (OSA). A phase 2 safety and efficacy study evaluating Qsymia in patients with OSA showed that patients who took Qsymia had improvements in sleep apnea events (apnea-hypopnea events) and lost more weight than those who took placebo.<ref></ref> | Qsymia is also in phase 2 clinical development for the treatment of type 2 diabetes and ] (OSA). A phase 2 safety and efficacy study evaluating Qsymia in patients with OSA showed that patients who took Qsymia had improvements in sleep apnea events (apnea-hypopnea events) and lost more weight than those who took placebo.<ref></ref> | ||
| Further analyses from clinical studies demonstrated that Qsymia improves blood pressure.<ref></ref> Dr. Suzanne Oparil of the ] stated “The higher the dose, the more weight loss and the more blood pressure went down” presented at the American Society of Hypertension’s 25th annual meeting in New York.<ref></ref> | Further analyses from clinical studies demonstrated that Qsymia improves blood pressure.<ref></ref> Dr. Suzanne Oparil of the ] stated “The higher the dose, the more weight loss and the more blood pressure went down” presented at the American Society of Hypertension’s 25th annual meeting in New York.<ref></ref> | ||
| Her co-authored study was subsequently accepted and published by the American Journal of Cardiology.19<ref></ref> | Her co-authored study was subsequently accepted and published by the American Journal of Cardiology.19<ref></ref> | ||
| ==References== | ==References== | ||
Revision as of 08:20, 8 November 2013
Pharmaceutical compound | |
 | |
| Combination of | |
|---|---|
| Phentermine | Appetite suppressant/stimulant of the amphetamine and phenethylamine class |
| Topiramate | Anticonvulsant |
| Clinical data | |
| Trade names | Qsymia |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| (verify) | |
The combination of the drugs phentermine and topiramate (trade name Qsymia, formerly Qnexa) is a medication indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: ≥30 kg/m or ≥27 kg/m (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia. In clinical trials, Qsymia was associated with significant weight loss when compared with placebo. This weight loss was associated with improvements in weight-related comorbidities such as improved glycemia, decreased blood pressure, and improved cholesterol.
Qsymia was developed by Vivus, Inc., a California pharmaceutical company. Phentermine is a sympathomimetic amine which acts as an appetite suppressant and stimulant. Topiramate is an anticonvulsant that has weight loss side effects. The exact mechanism of action for both drugs is unknown.
On February 22, 2012, U.S. Food and Drug Administration (FDA) advisors voted 20 to 2 to recommend that the FDA adopt phentermine/topiramate ER for chronic weight management. On July 17, 2012, the U.S. FDA approved Qsymia as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: ≥30 kg/m or ≥27 kg/m (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia. Qsymia is available in certified retail pharmacies nationwide and also available through a certified mail-order pharmacy network.
Available Doses
The following doses of phentermine IR (immediate-release) and topiramate ER were used in Phase 3 testing:
• Top dose: phentermine 15 mg and topiramate ER 92 mg
• Recommended dose: phentermine 7.5 mg and topiramate ER 46 mg
• Starting dose: phentermine 3.75 mg and topiramate ER 23 mg
Safety and effectiveness
Qsymia clinical trials have shown significant weight loss among subjects receiving Qsymia when compared with placebo. The Phase 3 56-week EQUIP and CONQUER studies showed an average weight loss of 8% to 11% with the recommended dose or top dose (ITT-LOCF). In addition, 62% to 70% of subjects receiving the recommended dose or top dose of Qsymia achieved ≥5% weight by week 56 (ITT-LOCF).
The most common adverse events which occurred at a rate ≥5% and ≥1.5 times placebo included paraesthesia (tingling in fingers/toes), dizziness, dysguesia, insomnia, constipation, and dry mouth.
Qsymia is contraindicated in pregnancy, glaucoma, hyperthyroidism, during or within 14 days of taking monoamine oxidase inhibitors, and in patients with hypersensitivity or idiosyncrasy to sympathomimetic amines. Qsymia can cause an increase in resting heart rate.
Qsymia can cause fetal harm. Data from pregnancy registries and epidemiology studies indicate that a fetus exposed to topiramate, a component of Qsymia, in the first trimester of pregnancy has an increased risk of oral clefts (cleft lip with or without cleft palate). If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be apprised of the potential hazard to a fetus. Females of reproductive potential should have a negative pregnancy test before starting Qsymia and monthly thereafter during Qsymia therapy. Females of reproductive potential should use effective contraception during Qsymia therapy.
Qsymia Risk Evaluation and Mitigation Strategy (REMS)
Qsymia was approved with a REMS to assure that benefits of treatment outweigh the risks. Because of the teratogenic risk associated with Qsymia therapy, Qsymia is available through a limited program under the REMS. Under the Qsymia REMS, only certified pharmacies may distribute Qsymia. Further information, is available at www.QsymiaREMS.com or by telephone at 1-888-998-4887.
Key Publications
EQUIP Investigated the safety and efficacy of the combination for 56 weeks in severely obese patients (BMI ≥35 kg/m2); published in Obesity.
CONQUER A 56-week safety and efficacy trial, evaluating obese or overweight patients (BMI ≥27 and ≤45 kg/m2) with ≥2 weight-related comorbidities (such as type 2 diabetes, hypertension, dyslipidemia); published in The Lancet.
SEQUEL A 52-week extension of CONQUER, collecting long-term data over 108 weeks.
Approval history
In December 2009 VIVUS submitted a new drug application (NDA) to the FDA and on March 1, 2010, Vivus announced that the FDA accepted the NDA for review.
In October 2010, the FDA announced its decision to not approve Qsymia in its current form and issued a Complete Response Letter (CRL) to VIVUS due to lack of long-term data and concerns about side effects including elevated heart rate, major adverse cardiovascular events, and birth defects.
The FDA expressed concerns about the potential for Qsymia to cause birth defects and requested that Vivus assess the feasibility of analyzing existing healthcare databases to determine the historical incidence of oral cleft in offspring of women treated with topiramate for migraine prophylaxis (100 mg).
In October 2011, VIVUS resubmitted the NDA to the FDA with responses to the issues addressed in the CRL. The FDA accepted the NDA in November 2011.
On February 22, 2012, US FDA advisors on the Endocrine and Metabolism Advisory Committee voted 20 to 2 to recommend that the FDA adopt phentermine/topiramate ER for chronic weight management.
The drug’s name was changed from Qnexa to Qsymia, and approved by the FDA on July 17, 2012.
On September 18, 2012, Qsymia became available on the US market.
Patents and other indications
Vivus currently has four U.S. patents covering Qsymia. These patents are related to the product and methods of using the drug in various therapeutic applications.
Qsymia is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea (OSA). A phase 2 safety and efficacy study evaluating Qsymia in patients with OSA showed that patients who took Qsymia had improvements in sleep apnea events (apnea-hypopnea events) and lost more weight than those who took placebo.
Further analyses from clinical studies demonstrated that Qsymia improves blood pressure. Dr. Suzanne Oparil of the University of Alabama at Birmingham stated “The higher the dose, the more weight loss and the more blood pressure went down” presented at the American Society of Hypertension’s 25th annual meeting in New York. Her co-authored study was subsequently accepted and published by the American Journal of Cardiology.19
References
- Vivus Inc.
- http://ir.vivus.com/releasedetail.cfm?ReleaseID=692685
- http://ir.vivus.com/releasedetail.cfm?ReleaseID=447799
- http://ir.vivus.com/releasedetail.cfm?ReleaseID=620724
- http://usatoday30.usatoday.com/news/health/story/2012-07-18/qsymia-diet-drug-approval/56271594/1